Please note: The information displayed on this page might be outdated.
Eidos Therapeutics : Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Listing
Public, USA
Market Cap
1B +
Website:
Address:
101 Montgomery St
Suite 2550
San Francisco, CA 94104
United States

Company Participants at Class of 2018 Biotech IPO Investor Day

  • Cameron Turtle, CBO

Top 10 Holders of Eidos Therapeutics Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
RA Capital Management LLC 4.80 1,798,339 145.92 Stakes 10/5/20
Aisling Capital Management LP 3.00 1,123,630 91.17 13F 9/30/20
Cormorant Asset Management LP 2.65 993,185 80.59 13F 9/30/20
BlackRock Fund Advisors 1.88 705,156 57.22 13F 9/30/20
Vanguard Group, Inc. (Subfiler) 1.87 702,806 57.03 13F 9/30/20
Perceptive Advisors LLC 1.83 686,922 55.74 13F 9/30/20
The Vanguard Group, Inc. 1.75 655,173 53.16 Funds 10/31/20
Redmile Group LLC 1.24 466,205 37.83 13F 9/30/20
Artisan Partners Holdings LP 1.15 430,709 34.95 13F 9/30/20
Gilder, Gagnon, Howe & Co. LLC 0.89 335,349 27.21 13F 9/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.